Neurodevelopmental pathways to aggression: A model to understand and target treatment in youth

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 18, Issue 3, 2006, Pages 302-317

  Sugden, Steven G ^a   Kile, Shawn J ^a   Hendren, Robert L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CLONIDINE; DECANOIC ACID; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GUANFACINE; LITHIUM; METHYLPHENIDATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OXCARBAZEPINE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM; VALPROIC ACID;

AGGRESSION; ANXIETY; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BRAIN FUNCTION; BRAIN REGION; COGNITIVE DEFECT; COGNITIVE THERAPY; DELUSION; DRUG DEPENDENCE; HALLUCINATION; HUMAN; IMPULSIVENESS; MENTAL INSTABILITY; MORNING DOSAGE; NERVE CELL DIFFERENTIATION; NEUROANATOMY; NEUROBIOLOGY; NONHUMAN; PARANOIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEXUAL AROUSAL DISORDER; ADOLESCENT; AROUSAL; CASE REPORT; CHILD; COGNITION; FEMALE; GROWTH, DEVELOPMENT AND AGING; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; MOOD DISORDER; NERVOUS SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ADOLESCENT; ADRENERGIC AGENTS; AGGRESSION; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; AROUSAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COGNITION; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMPULSIVE BEHAVIOR; MALE; MOOD DISORDERS; NERVOUS SYSTEM;

EID: 85047683979     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2006.18.3.302     Document Type: Review

References (111)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text-Revision (DSM-IVTR). Washington, DC, American Psychiatric Association, 2000
2. Miczek KA, Fish EW, De Bold JF, et al: Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems. Psychopharmacology (Berl) 2002; 163:434-458
3. Moyer K: The Psychobiology of Aggression. New York, Harper & Row, 1976
4. Vitiello B, Stoff DM: Subtypes of aggression and their relevance to child psychiatry. J Am Acad Child Adolesc Psychiatry 1997; 36:307-315
5. Pennington BF: The Development of Psychopathology: Nature and Nurture. New York, Guilford, 2002
6. Moeller FG, Barratt ES, Dougherty DM, et al: Psychiatric aspects of impulsivity. Am J Psychiatry 2001; 158:1783-1793
7. Siever LJ, Buchsbaum MS, New AS, et al: d,l-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology 1999; 20:413-423
8. Max JE, Robertson BA, Lansing AE: The phenomenology of personality change due to traumatic brain injury in children and adolescents. J Neuropsychiatry Clin Neurosci 2001; 13:161-170
9. Brent DA, Oquendo M, Birmaher B, et al: Peripubertal suicide attempts in offspring of suicide attempters with siblings concordant for suicidal behavior. Am J Psychiatry 2003; 160:1486-1493
10. Spear LP: The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000; 24:417-463
11. Barkley RA: Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997; 121:65-94
12. Volavka J: The neurobiology of violence: an update. J Neuropsychiatry Clin Neurosci 1999; 11:307-314
13. Bechara A: Neurobiology of decision-making: risk and reward. Semin Clin Neuropsychiatry 2001; 6:205-216
14. Pietrini P, Guazzelli M, Basso G, et al: Neural correlates of imaginal aggressive behavior assessed by positron emission tomography in healthy subjects. Am J Psychiatry 2000; 157:1772-1781
15. Hollander E, Evers M: New developments in impulsivity. Lancet 2001; 358:949-650
16. Bechara A, Damasio H, Damasio AR: Role of the amygdala in decision-making. Ann N Y Acad Sci 2003; 985:356-369
17. Davidson RJ, Putnam KM, Larson CL: Dysfunction in the neural circuitry of emotion regulation - a possible prelude to violence. Science 2000; 289:591-594
18. Hinshaw SP: Impulsivity, emotion regulation, and developmental psychopathology: specificity versus generality of linkages. Ann N Y Acad Sci 2003; 1008:149-159
19. Higley JD, Linnoila M: Low central nervous system serotonergic activity is traitlike and correlates with impulsive behavior: a nonhuman primate model investigating genetic and environmental influences on neurotransmission. Ann N Y Acad Sci 1997; 836:39-56
20. Kruesi MJ, Rapoport JL, Hamburger S, et al: Cerebrospinal fluid monoamine metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry 1990; 47:419-426
21. Krakowski M: Violence and serotonin: influence of impulse control, affect regulation, and social functioning. J Neuropsychiatry Clin Neurosci 2003; 15:294-305
22. Hollander E, DeCaria CM, Finkell JN, et al: A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000; 47:813-817
23. Evans J, Reeves B, Platt H, et al: Impulsiveness, serotonin genes and repetition of deliberate self-harm (DSH). Psychol Med 2000; 30:1327-1334
24. Brunner D, Hen R: Insights into the neurobiology of impulsive behavior from serotonin receptor knockout mice. Ann N Y Acad Sci 1997; 836:81-105
25. Leibenluft E, Charney DS, Towbin KE, et al: Defining clinical phenotypes of juvenile mania. Am J Psychiatry 2003; 160:430-437
26. Fox NA: Temperament and regulation of emotion in the first years of life. Pediatrics 1998; 102:1230-1235
27. Bhangoo RK, Leibenluft E: Affective neuroscience and the study of normal and abnormal emotion regulation. Child Adolesc Psychiatr Clin N Am 2002; 11:519-532
28. Wozniak J: Pediatric bipolar disorder: the new perspective on severe mood dysfunction in children. J Child Adolesc Psychopharmacol 2003; 13:449-451
29. Phillips ML, Drevets WC, Rauch SL, et al: Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry 2003; 54:515-528
30. Nakaji P, Meltzer HS, Singel SA, et al: Improvement of aggressive and antisocial behavior after resection of temporal lobe tumors. Pediatrics 2003; 112:e430
31. Blumberg HP, Kaufman J, Martin A, et al: Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry 2003; 60:1201-1208
32. Dougherty DD, Shin LM, Alpert NM, et al: Anger in healthy men: a PET study using script-driven imagery. Biol Psychiatry 1999; 46:466-472
33. Critchley HD, Simmons A, Daly EM, et al: Prefrontal and medial temporal correlates of repetitive violence to self and others. Biol Psychiatry 2000; 47:928-934
34. Wagner KD, Ambrosini PJ: Childhood depression: pharmacological therapy/treatment (pharmacotherapy of childhood depression). J Clin Child Psychol 2001; 30:88-97
35. Melia KR, Duman RS: Involvement of corticotropin-releasing factor in chronic stress regulation of the brain noradrenergic system. Proc Natl Acad Sci U S A; 1991; 88:8382-8386
36. Uno H, Tarara R, Else JG, et al: Hippocampal damage associated with prolonged and fatal stress in primates. J Neurosci 1989; 9:1705-1711
37. Luine V, Villegas M, Martinez C, et al: Repeated stress causes reversible impairments of spatial memory performance. Brain Res 1994; 639:167-170
38. Bremner JD: Long-term effects of childhood abuse on brain and neurobiology. Child Adolesc Psychiatr Clin N Am 2003; 12:271-292
39. Teicher MH, Andersen SL, Polcari A, et al: The neurobiological consequences of early stress and childhood maltreatment. Neurosci Biobehav Rev 2003; 27:33-44
40. Herman JP, Cullinan WE: Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 1997; 20:78-84
41. Amaral DG, Corbett BA: The amygdala, autism and anxiety. Novartis Found Symp 2003; 251:177-187; discussion 187-197, 281-297
42. Pavic L, Gregurek R, Petrovic R, et al: Alterations in brain activation in posttraumatic stress disorder patients with severe hyperarousal symptoms and impulsive aggressiveness. Eur Arch Psychiatry Clin Neurosci 2003; 253:80-83
43. Dunn JD, Whitener J: Plasma corticosterone responses to electrical stimulation of the amygdaloid complex: cytoarchitectural specificity. Neuroendocrinology 1986; 42:211-217
44. Takao K, Nagatani T, Kitamura Y, et al: Effects of corticosterone on 5-HT1A and 5-HT2 receptor binding and on the receptor-mediated behavioral responses of rats. Eur J Pharmacol 1997; 333:123-128
45. Gingrich JA, Hen R: Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology (Berl) 2001; 155:1-10
46. Donnelly CL: Pharmacologic treatment approaches for children and adolescents with posttraumatic stress disorder. Child Adolesc Psychiatr Clin N Am 2003; 12:251-269
47. Abercrombie ED, Jacobs BL: Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats: II: adaptation to chronically presented stressful stimuli. J Neurosci 1987; 7:2844-2848
48. Lewis DO, Moy E, Jackson LD, et al: Biopsychosocial characteristics of children who later murder: a prospective study. Am J Psychiatry 1985; 142:1161-1167
49. Hogarty GE, Flesher S, Ulrich R, et al: Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 2004; 61:866-876
50. Foley SR, Kelly BD, Clarke M, et al: Incidence and clinical correlates of aggression and violence at presentation in patients with first episode psychosis. Schizophr Res 2005; 72:161-168
51. Moran P, Walsh E, Tyrer P, et al: Impact of comorbid personality disorder on violence in psychosis: report from the UK700 trial. Br J Psychiatry 2003; 182:129-134
52. Nelson MD, Saykin AJ, Flashman LA, et al: Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiatry 1998; 55:433-440
53. Pearlson GD, Marsh L: Structural brain imaging in schizophrenia: a selective review. Biol Psychiatry 1999; 46:627-649
54. Lipska BK, Weinberger DR: To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000; 23:223-239
55. Heckers S, Rauch SL, Goff D, et al: Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1998; 1:318-323
56. Weinberger DR, Berman KF, Suddath R, et al: Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 1992; 149:890-897
57. Combs DR, Penn DL: The role of subclinical paranoia on social perception and behavior. Schizophr Res 2004; 69:93-104
58. Lindstrom LH, Gefvert O, Hagberg G, et al: Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999; 46:681-688
59. Breier A, Su TP, Saunders R, et al: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997; 94:2569-2574
60. Carlsson A, Waters N, Holm-Waters S, et al: Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001; 41:237-260
61. Berridge KC, Robinson TE: What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998; 28:309-369
62. Kapur S: Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160:13-23
63. Lehman AF, Lieberman JA, Dixon LB, et al: Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004; 161:1-56
64. Vitaro F, Brendgen M, Tremblay RE: Reactively and proactively aggressive children: antecedent and subsequent characteristics. J Child Psychol Psychiatry 2002; 43:495-505
65. Raine A, Meloy JR, Bihrle S, et al: Reduced prefrontal and increased subcortical brain functioning assessed using positron emission tomography in predatory and affective murderers. Behav Sci Law 1998; 16:319-332
66. Raine A, Lencz T, Bihrle S, et al: Reduced prefrontal gray matter volume and reduced autonomic activity in antisocial personality disorder. Arch Gen Psychiatry 2000; 57:119-127; discussion 128-129
67. Smith DA, Flynn JP: Afferent projections to quiet attack sites in cat hypothalamus. Brain Res 1980; 194:29-40
68. Shaikh MB, Lu CL, MacGregor M, et al: Dopaminergic regulation of quiet biting attack behavior in the cat. Brain Res Bull 1991; 27:725-730
69. Schultz W, Dayan P, Montague PR: A neural substrate of prediction and reward. Science 1997; 275:1593-1599
70. Henggeler SW, Schoenwald SK, Rowland MD, et al: Serious Emotional Disturbance in Children and Adolescents: Multisystemic Therapy. New York, Guilford, 2002
71. Kazdin AE: Treatments for aggressive and antisocial children. Child Adolesc Psychiatr Clin N Am 2000; 9:841-858
72. Pliszka SR: Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implications for management. Paediatr Drugs 2003; 5:741-750
73. McDougle CJ, Stigler KA, Posey DJ: Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry 2003; 64(suppl 4):16-25
74. Klein RG, Abikoff H, Klass E, et al: Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54:1073-1080
75. Connor DF, Barkley RA, Davis HT: A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 2000; 39:15-25
76. Steketee JD: Neurotransmitter systems of the medial prefrontal cortex: potential role in sensitization to psychostimulants. Brain Res Brain Res Rev 2003; 41:203-228
77. Volkow ND, Fowler JS, Wang G, et al: Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 2002; 6(suppl 1):31-43
78. Durston S: A review of the biological bases of ADHD: what have we learned from imaging studies? Ment Retard Dev Disabil Res Rev 2003; 9:184-195
79. Castellanos FX: Toward a pathophysiology of attention-deficit/ hyperactivity disorder. Clin Pediatr (Phila) 1997; 36:381-393
80. Arnsten AFT: Dopaminergic and noradrenergic influences on cognitive functions mediated by prefrontal cortex, in Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. Edited by Solanto MV, Arnsten FT. London, Oxford University Press, 2001, pp 185-208
81. Carlson GA, Mick E: Drug-induced disinhibition in psychiatrically hospitalized children. J Child Adolesc Psychopharmacol 2003; 13:153-163
82. Coccaro EF, Kavoussi RJ, Hauger RL: Serotonin function and antiaggressive response to fluoxetine: a pilot study. Biol Psychiatry 1997; 42:546-552
83. Kavoussi RJ, Coccaro EF: Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998; 59:676-680
84. Bel N, Artigas F: Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993; 15:243-245
85. Wegerer V, Moll GH, Bagli M, et al: Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J Child Adolesc Psychopharmacol 1999; 9:13-24; discussion 25-26
86. Meyer JH, Kapur S, Eisfeld B, et al: The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry 2001; 158:78-85
87. Drevets WC: Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 1999; 877:614-637
88. van Praag HM, Asnis GM, Kahn RS, et al: Monoamines and abnormal behaviour: a multi-aminergic perspective. Br J Psychiatry 1990; 157:723-734
89. Konradi C, Heckers S: Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001; 50:729-742
90. Liddle PF, Lane CJ, Ngan ET: Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. Br J Psychiatry 2000; 177:402-407
91. Cohen BM, Cherkerzian S, Ma J, et al: Cells in midline thalamus, central amygdala, and nucleus accumbens responding specifically to antipsychotic drugs. Psychopharmacology (Berl) 2003; 167:403-410
92. McElroy SL: Recognition and treatment of DSM-IV intermittent explosive disorder. J Clin Psychiatry 1999; 60(suppl 15):12-16
93. Hollander E, Dolgoff-Kaspar R, Cartwright C, et al: An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001; 62:530-534
94. Steiner H, Saxena K, Chang K: Psychopharmacologic strategies for the treatment of aggression in juveniles. CNS Spectr 2003; 8:298-308
95. Donovan SJ, Stewart JW, Nunes EV, et al: Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000; 157:818-820
96. Hollander E, Tracy KA, Swann AC, et al: Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003; 28:1186-1197
97. Lindenmayer JP, Kotsaftis A: Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000; 61:123-128
98. Malone RP, Bennett DS, Luebbert JF, et al: Aggression classification and treatment response. Psychopharmacol Bull 1998; 34:41-45
99. Manji HK, Moore GJ, Chen G: Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000; 48:740-754
100. Moore GJ, Bebchuk JM, Wilds IB, et al: Lithium-induced increase in human brain grey matter. Lancet 2000; 356:1241-1242
101. Pachet AK: Differential neuropychological performance of bipolar mood disorder patients treated with divalproex sodium or lithium carbonate. Dissertation Abstracts Int. 2000; 60
102. Puente RM: The use of carbamazepine in the treatment of behavioural disorders in children, in Epileptic Seizures-Behaviour-Pain. Edited by Bern BW. Switzerland, Hans Huber, 1976, pp 273-247
103. Cueva JE, Overall JE, Small AM, et al: Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996; 35:480-490
104. Gaudino MP, Smith MJ, Matthews DT: Use of oxcarbazepine for treatment-resistant aggression. Psychiatr Serv 2003; 54:1166-1167
105. MacDonald E, Scheinin M: Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system. J Physiol Pharmacol 1995; 46:241-258
106. Arnsten AFT, Steere JC, Hunt RD: The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function: potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53:448-455
107. Coull JT, Nobre AC, Frith CD: The noradrenergic alpha2 agonist clonidine modulates behavioural and neuroanatomical correlates of human attentional orienting and alerting. Cereb Cortex 2001; 11:73-84
108. Durlak JA, Fuhrman T, Lampman C: Effectiveness of cognitive-behavior therapy for maladapting children: a meta-analysis. Psychol Bull 1991; 110:204-214
109. Goldbeck L, Schmid K: Effectiveness of autogenic relaxation training on children and adolescents with behavioral and emotional problems. J Am Acad Child Adolesc Psychiatry 2003; 42: 1046-1054
110. Kazdin AE, Whitley MK: Treatment of parental stress to enhance therapeutic change among children referred for aggressive and antisocial behavior. J Consult Clin Psychol 2003; 71:504-515
111. Goldapple K, Segal Z, Garson C, et al: Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004; 61:34-41